| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Product candidate license acquisitions | 5,000 | - |
| Net cash used in investing activities | -158,522 | -198,565 |
| Payment of deferred offering costs | 3,324 | - |
| Proceeds from royalty obligation | 75,000 | - |
| Proceeds from exercise of stock options | 2,485 | 1,821 |
| Proceeds from issuance of common stock under employee stock purchase plan | 276 | - |
| Net cash provided by financing activities | 74,437 | 1,821 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -263 | -288 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -204,267 | -275,826 |
| Cash and cash equivalents at beginning of period | 319,832 | - |
| Cash and cash equivalents at end of period | 115,565 | - |
Zenas BioPharma, Inc. (ZBIO)
Zenas BioPharma, Inc. (ZBIO)